Dr. Michael Serzan explains the importance of clinical trial enrollment for patients with kidney cancer and highlighted findings from the STELLA-002 trial.
I finally felt like a survivor the day I heard my 18-month scans were clear, shifting from fear to faith and realizing I was not just surviving — I was thriving.